Neuromuscular blocking effects of vecuronium in dogs with autosomal-recessive centronuclear myopathy

Manuel Martin-Flores Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.
Department of Animal Science, College of Agriculture and Life Sciences, Cornell University, Ithaca, NY 14853.

Search for other papers by Manuel Martin-Flores in
Current site
Google Scholar
PubMed Close
 DVM
,
Monique D. Paré Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by Monique D. Paré in
Current site
Google Scholar
PubMed Close
 DVM
,
Emily A. Tomak Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by Emily A. Tomak in
Current site
Google Scholar
PubMed Close
,
Morgan L. Corn Department of Animal Science, College of Agriculture and Life Sciences, Cornell University, Ithaca, NY 14853.

Search for other papers by Morgan L. Corn in
Current site
Google Scholar
PubMed Close
 BSc
, and
Luis Campoy Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by Luis Campoy in
Current site
Google Scholar
PubMed Close
 DVM
DOI:
https://doi.org/10.2460/ajvr.76.4.302
Volume/Issue:
Volume 76: Issue 4
Online Publication Date:
01 Apr 2015
Restricted access
Sign In Reprints and Permissions Purchase Article

Abstract

OBJECTIVE To evaluate the potency of vecuronium and duration of vecuronium-induced neuromuscular blockade in dogs with centronuclear myopathy (CNM).

ANIMALS 6 Labrador Retrievers with autosomal-recessive CNM and 5 age- and weight-matched control dogs.

PROCEDURES Dogs were anesthetized on 2 occasions (1-week interval) with propofol, dexmedetomidine, and isoflurane. Neuromuscular function was monitored with acceleromyography and train-of-four (TOF) stimulation. In an initial experiment, potency of vecuronium was evaluated by a cumulative-dose method, where 2 submaximal doses of vecuronium (10 μg/kg each) were administered IV sequentially. For the TOF's first twitch (T1), baseline twitch amplitude and maximal posttreatment depression of twitch amplitude were measured. In the second experiment, dogs received vecuronium (50 μg/kg, IV) and the time of spontaneous recovery to a TOF ratio (ie, amplitude of TOF's fourth twitch divided by amplitude of T1) ≥ 0.9 and recovery index (interval between return of T1 amplitude to 25% and 75% of baseline) were measured.

RESULTS Depression of T1 after each submaximal dose of vecuronium was not different between groups. Median time to a TOF ratio ≥ 0.9 was 76.7 minutes (interquartile range [IQR; 25th to 75th percentile], 66.7 to 99.4 minutes) for dogs with CNM and 75.0 minutes (IQR, 47.8 to 96.5 minutes) for controls. Median recovery index was 18.0 minutes (IQR, 9.7 to 23.5 minutes) for dogs with CNM and 20.2 minutes (IQR, 8 to 25.1 minutes) for controls.

CONCLUSIONS AND CLINICAL RELEVANCE For the study dogs, neither potency nor duration of vecuronium-induced neuromuscular blockade was altered by CNM. Vecuronium can be used to induce neuromuscular blockade in dogs with autosomal-recessive CNM.

Abstract

OBJECTIVE To evaluate the potency of vecuronium and duration of vecuronium-induced neuromuscular blockade in dogs with centronuclear myopathy (CNM).

ANIMALS 6 Labrador Retrievers with autosomal-recessive CNM and 5 age- and weight-matched control dogs.

PROCEDURES Dogs were anesthetized on 2 occasions (1-week interval) with propofol, dexmedetomidine, and isoflurane. Neuromuscular function was monitored with acceleromyography and train-of-four (TOF) stimulation. In an initial experiment, potency of vecuronium was evaluated by a cumulative-dose method, where 2 submaximal doses of vecuronium (10 μg/kg each) were administered IV sequentially. For the TOF's first twitch (T1), baseline twitch amplitude and maximal posttreatment depression of twitch amplitude were measured. In the second experiment, dogs received vecuronium (50 μg/kg, IV) and the time of spontaneous recovery to a TOF ratio (ie, amplitude of TOF's fourth twitch divided by amplitude of T1) ≥ 0.9 and recovery index (interval between return of T1 amplitude to 25% and 75% of baseline) were measured.

RESULTS Depression of T1 after each submaximal dose of vecuronium was not different between groups. Median time to a TOF ratio ≥ 0.9 was 76.7 minutes (interquartile range [IQR; 25th to 75th percentile], 66.7 to 99.4 minutes) for dogs with CNM and 75.0 minutes (IQR, 47.8 to 96.5 minutes) for controls. Median recovery index was 18.0 minutes (IQR, 9.7 to 23.5 minutes) for dogs with CNM and 20.2 minutes (IQR, 8 to 25.1 minutes) for controls.

CONCLUSIONS AND CLINICAL RELEVANCE For the study dogs, neither potency nor duration of vecuronium-induced neuromuscular blockade was altered by CNM. Vecuronium can be used to induce neuromuscular blockade in dogs with autosomal-recessive CNM.

Contributor Notes

Dr. Paré's present address is Département de sciences cliniques, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada.

Ms. Corn's present address is Water4Dogs Rehabilitation Center, 77 Worth St, New York, NY 10013.

Address correspondence to Dr. Martin-Flores (martinflores@cornell.edu).
Cover American Journal of Veterinary Research
American Journal of Veterinary Research
Publication Date:
01 Apr 2015

  • 1. Spiro AJ, Shy GM, Gonatas NK. Myotubular myopathy. Persistence of fetal muscle in an adolescent boy. Arch Neurol 1966; 14: 1–14.

  • 2. Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis 2008; 3: 26–1172–3–26.

  • 3. Kramer JW, Hegreberg GA, Bryan GM, et al. A muscle disorder of Labrador Retrievers characterized by deficiency of type II muscle fibers. J Am Vet Med Assoc 1976; 169: 817–820.

    • Search Google Scholar
    • Export Citation

  • 4. McKerrell RE, Braund KG. Hereditary myopathy in Labrador Retrievers: clinical variations. J Small Anim Pract 1987; 28: 479–489.

  • 5. Watson AD, Farrow BR, Middleton DJ, et al. Myopathy in a Labrador Retriever. Aust Vet J 1988; 65: 226–227.

  • 6. Gortel K, Houston DM, Kuiken T, et al. Inherited myopathy in a litter of Labrador Retrievers. Can Vet J 1996; 37: 108–110.

  • 7. Pelé M, Tiret L, Kessler JL, et al. SINE exonic insertion in the PTPLA gene leads to multiple splicing defects and segregates with the autosomal recessive centronuclear myopathy in dogs. Hum Mol Genet 2005; 14: 1417–1427.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 8. Bley T, Gaillard C, Bilzer T, et al. Genetic aspects of Labrador Retriever myopathy. Res Vet Sci 2002; 73: 231–236.

  • 9. Muenster T, Schmidt J, Wick S, et al. Rocuronium 0.3 mg × kg−1 (ED95) induces a normal peak effect but an altered time course of neuromuscular block in patients with Duchenne's muscular dystrophy. Paediatr Anaesth 2006; 16: 840–845.

    • Search Google Scholar
    • Export Citation

  • 10. Schmidt J, Muenster T, Wick S, et al. Onset and duration of mivacurium-induced neuromuscular block in patients with Duchenne muscular dystrophy. Br J Anaesth 2005; 95: 769–772.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 11. Kopman AF, Kumar S, Klewicka MM, et al. The staircase phenomenon: implications for monitoring of neuromuscular transmission. Anesthesiology 2001; 95: 403–407.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 12. Martin-Flores M, Lau EJ, Campoy L, et al. Twitch potentiation: a potential source of error during neuromuscular monitoring with acceleromyography in anesthetized dogs. Vet Anaesth Analg 2011; 38: 328–335.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 13. Fuchs-Buder T, Claudius C, Skovgaard LT, et al. Good clinical research practice in pharmacodynamics studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 2007; 51: 789–808.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 14. Kopman AF, Lien CA, Naguib M. Neuromuscular dose-response studies: determining sample size. Br J Anaesth 2011; 106: 194–198.

  • 15. Donlon JV Jr, Savarese JJ, Ali HH, et al. Human dose-response curves for neuromuscular blocking drugs: a comparison of two methods of construction and analysis. Anesthesiology 1980; 53: 161–166.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 16. Martin-Flores M, Sakai DM, Campoy L, et al. Recovery from neuromuscular block in dogs: restoration of spontaneous ventilation does not exclude residual blockade. Vet Anaesth Analg 2014; 41: 269–277.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 17. Bom A, Hope F, Rutherford S, et al. Preclinical pharmacology of sugammadex. J Crit Care 2009; 24: 29–35.

  • 18. Kariman A, Clutton RE. The effects of medetomidine on the action of vecuronium in dogs anaesthetized with halothane and nitrous oxide. Vet Anaesth Analg 2008; 35: 400–408.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 19. Breslin D, Reid J, Hayes A, et al. Anaesthesia in myotubular (centronuclear) myopathy. Anaesthesia 2000; 55: 471–474.

  • 20. Costi D, van der Walt JH. General anesthesia in an infant with X-linked myotubular myopathy. Paediatr Anaesth 2004; 14: 964–968.

  • 21. Driessen JJ, Robertson EN, Booij LH. Acceleromyography in neonates and small infants: baseline calibration and recovery of the responses after neuromuscular blockade with rocuronium. Eur J Anaesthesiol 2005; 22: 11–15.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement